Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Multiple Internal Champions Can Propel Complex Licensing Deals, Pfizer Exec Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Incyte deal is a model for negotiations involving multiple therapeutic areas, Pfizer exec tells licensing meeting.

You may also be interested in...



Millennium Shops Atherosclerosis Candidate After Positive Phase II

Biopharma seeks a partner before bringing the CCR2 antagonist into Phase III, firm tells “The Pink Sheet” DAILY.

Millennium Shops Atherosclerosis Candidate After Positive Phase II

Biopharma seeks a partner before bringing the CCR2 antagonist into Phase III, firm tells “The Pink Sheet” DAILY.

Incyte’s CCR5 Antagonist Has “Meaningful Advantages” Over Pfizer’s Maraviroc, Firm Says

Company says it is in active licensing discussions with “probably half a dozen” firms.

Topics

UsernamePublicRestriction

Register

PS064844

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel